Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of topical sofpironium, which has been shown to be partially metabolized by the isoenzyme. In a pharmacokinetic study in patients with primary axillary hyperhidrosis, sofpironium systemic exposure (AUC) and peak plasma concentration (Cmax) increased approximately 2 -fold following concomitant use with the potent CYP450 2D6 inhibitor paroxetine at a 20 mg oral dose.

MANAGEMENT: Coadministration of topical sofpironium with potent CYP450 2D6 inhibitors should generally be avoided. If coadministration is required, monitor for sofpironium-related adverse effects which include blurred vision, urinary retention, difficulty controlling body temperature in warm environments, and dry mouth.